Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.16    0.00 (0.00%)
Bid:
0.15
Ask:
0.17
Spread: 0.02 (13.333%)
Market Cap: £2.11m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Final Results

23 Jun 2005 14:42

AZURE HOLDINGS PLC PRELIMINARY ANNOUNCEMENT OF RESULTS YEAR ENDED 31 DECEMBER 2004 Chairman's StatementI am pleased to present my report for the year ended 31 December 2004.Your Company is still seeking a suitable merger target. During the period, theCompany entered into discussions with an acquisition target but the board couldnot agree commercial terms and talks were terminated.Your board is pursuing other acquisition targets which, owing to their size,may result in a reverse takeover.In the meantime, the directors have agreed not to draw their salaries and arefocused on keeping overheads to a minimum.Nicolas GreenstoneChairman23 June 2005Profit and loss accountfor the year ended 31 December 2004 Year ended Year ended 31 31 December December 2004 2003 ‚£'000 ‚£'000 Administrative expenses (345) (86) Profit on disposal of investments - 10 Operating loss (345) (76) Loss on disposal of subsidiary undertakings - (74) Loss on ordinary activities before taxation (345) (150) Taxation - - Loss on ordinary activities after taxation (345) (150) Loss per share (0.86p) (4.14p) Fully diluted loss per share (0.86p) (4.14p) The Group has no recognised gains and losses other than the loss for the year.Balance sheetas at 31 December 2004 2004 2003 ‚£'000 ‚£'000 Current assets Debtors 7 7 Cash at bank and in hand 14 119 21 126 Creditors: amounts falling due within one year (90) (59) Net current (liabilities)/assets (69) 67 Total assets less current liabilities (69) 67 Capital and reserves Called up share capital 5,475 5,304 Share premium account 10,279 10,241 Profit and loss account (15,823) (15,478) Equity shareholders' (deficit)/funds (69) 67 Cash flow statementfor the year ended 31 December 2004 2004 2003 ‚£'000 ‚£'000 Cash outflow from operating activities (225) (76) Financing Issue of equity shares 120 195 (Decrease)/increase in cash in the year (105) 119 Notes to the preliminary announcementfor the year ended 31 December 2004 1. Basis of preparation The financial information in this announcement does not constitute statutoryfinancial statements as defined in Section 240 of the Companies Act 1985. Theinformation relating to the year ended 31 December 2003 is an extract from thestatutory accounts for that year, which have been delivered to the Registrar ofCompanies. The auditors' report on those accounts was unqualified and did notcontain any statement under section 237(2) or (3) of the Companies Act 1985.The auditors have indicated that they will issue an unqualified report on thestatutory financial statements for the year ended 31 December 2004. Copies ofthe Company's Report and Financial Statements will be sent to shareholdersshortly and will be available at the registered office of the Company: OneGreat Cumberland Place, London W1H 7AL . 2. Going concern The financial statements have been prepared on a going concern basis inaccordance with applicable United Kingdom Accounting Standards.The directors have adopted this basis as they consider that the company hassufficient working capital to meet its obligations as they fall due.Chiddingfold Investments Limited, has agreed to fund the company's workingcapital requirements for a period until 30 June 2006, to the extent that suchcosts are not covered by other fund raisings or reverse acquisitiontransactions.During the year the Company made losses of ‚£345,000 and had net liabilities at31 December 2004 of ‚£69,000.The directors continue to actively seek suitable targets for a reverseacquisition.The directors have therefore prepared the financial statements on the goingconcern basis. The financial statements do not include any adjustments thatmight arise if this basis was inappropriate. 3. Basis of consolidation The consolidated financial statements include the financial statements of theCompany and have been prepared using both merger accounting principles andacquisition accounting principles.The Company has not presented its own profit and loss account as permitted bySection 230(3) of the Companies Act 1985. The Company's loss for the financialyear was ‚£345,000.4. Loss per shareLoss per share are calculated on a net basis using the loss on ordinaryactivities and the weighted average number of shares detailed below.In calculating fully diluted loss per share, the weighted average number ofshares is adjusted for the effect of dilutive share options issued under Groupshare option schemes. 2004 2003 ‚£'000 ‚£'000 Basic and diluted losses attributable to ordinary (345) (150)shareholders Number Number Weighted average number of ordinary shares 39,767,965 3,625,812 Dilutive share options - - Adjusted weighted average number of ordinary shares 39,767,965 3,625,812 Loss per share (0.86p) (4.14p) Fully diluted loss per share (0.86p) (4.14p) 5. Reconciliation of operating loss to net cash outflow from operating activities 2004 2003 ‚£'000 ‚£'000 Operating loss (345) (76) Decrease in debtors - 48 Increase/(decrease) in creditors 31 (48) Creditor settled via issue of shares 89 - Net cash outflow from operating activities (225) (76) 6. Reserves Share Profit and Total premium loss account account ‚£'000 ‚£'000 ‚£'000 At 1 January 2004 10,241 (15,478) (5,237) Loss for the year - (345) (345) Issue of shares 38 - 38 At 31 December 2004 10,279 (15,823) (5,544) 7. Taxation Factors affecting taxation:The tax charge for the year does not equate to the loss before tax at thestandard rate of corporation tax in the United Kingdom (30%). The differencesare explained below: 2004 2003 ‚£'000 ‚£'000 Loss on ordinary activities before taxation (345) (150) Loss on ordinary activities multiplied by the (104) (45)standard rate of corporation tax in the United Kingdom of 30% (2003: 30%) Effect of non-deductible expenses and addition to 104 45tax losses - - At 31 December 2004, the company had accumulated tax losses of ‚£817,627 arisingform management expenses and ‚£1,476,749 of capital losses. 8. Dividends The Directors are not proposing the payment of a dividend in respect of theyear ended 31 December, 2004.ENDAZURE HOLDINGS PLC
Date   Source Headline
31st Oct 20147:00 amRNSTotal Voting Rights
23rd Oct 201410:45 amRNSGrant of options
14th Oct 20147:00 amRNSApproved Clinical Trial Update
8th Oct 20144:12 pmRNSEarly Completion of Equity Swap Agreement
8th Oct 20144:08 pmRNSHolding(s) in Company
2nd Sep 20147:00 amRNSValiSeek Development Update
28th Aug 201411:33 amRNSHolding(s) in Company
19th Aug 20147:00 amRNSHalf Yearly Report
5th Aug 201412:05 pmRNSHolding(s) in Company
4th Aug 20147:00 amRNSNotice of Acceptance of CTA Request
1st Jul 201411:35 amRNSHolding(s) in Company
24th Jun 20147:00 amRNSDirector/PDMR Shareholding
18th Jun 20149:22 amRNSNew Corporate Website & New Office Address
10th Jun 20147:00 amRNSSubmission of Clinical Trial Application re VAL201
15th May 20147:00 amRNSValiSeek Development Update
1st May 20147:00 amRNSNew Japanese Patent Grant
23rd Apr 20144:29 pmRNSResult of AGM
17th Apr 20145:51 pmRNSHolding(s) in Company
8th Apr 20147:00 amRNSValiSeek Joint Venture
1st Apr 20147:00 amRNSVAL201 Update
31st Mar 20144:45 pmRNSNotice of AGM
31st Mar 20144:09 pmRNSHolding(s) in Company
28th Mar 20147:01 amRNSPosting of R&As and Notice of AGM
19th Mar 20147:00 amRNSFinal Results
20th Feb 20147:00 amRNSNew European Patent Grant
31st Jan 201412:45 pmRNSSale of shares in VolitionRx
22nd Jan 20143:00 pmRNSGrant of Options
16th Jan 20147:00 amRNSIssue of Equity
27th Dec 20137:00 amRNSFundraising and Equity Swap
5th Dec 20137:00 amRNSNew Australian Patent Grant
28th Nov 20137:00 amRNSUpdate re Positive VAL201 & Biomarker Unit Studies
15th Nov 20137:00 amRNSPlacing to raise £1m
1st Nov 20137:00 amRNSChange of Broker
24th Oct 20134:25 pmRNSRe: VAL201 - Update
8th Oct 20137:00 amRNSDirectorate Changes
5th Sep 20137:00 amRNSHalf Yearly Report
15th Aug 20137:00 amRNSConsortium incl. ValiRx Awarded Eurostars Grant
31st Jul 20137:00 amRNSUpdate
25th Jun 20137:00 amRNSInvestor Presentation in Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
13th Jun 20137:00 amRNSRe: VAL201 Update
6th Jun 201310:00 amRNSValiRx admitted as founder member of the SSE
25th Apr 20137:00 amRNSNew Patent Granted
22nd Apr 201311:52 amRNSResult of AGM
2nd Apr 20137:00 amRNSUpdate on Developmental and Clinical Activity
28th Mar 20137:01 amRNSFinal Results
21st Feb 20137:00 amRNSRe Commercial Development Update
23rd Jan 20137:00 amRNSAppointment of Medical Monitoring Officer
31st Dec 20127:00 amRNSTotal Voting Rights
22nd Nov 20127:00 amRNSRe: Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.